Patents by Inventor Isil Altintas

Isil Altintas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Multispecific antibodies against CD40 and CD137
    Patent number: 11939388
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: March 26, 2024
    Assignees: GENMAB A/S, BioNTech SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
  • HUMANIZED OR CHIMERIC CD3 ANTIBODIES
    Publication number: 20230374131
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: February 14, 2023
    Publication date: November 23, 2023
    Inventors: Edward Norbert VAN DEN BRINK, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Isil Altintas, Paul Parren, Rik Rademaker
  • Nucleic acid molecules encoding binding agents to CD40 and 4-1BB (CD137)
    Patent number: 11814411
    Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: November 14, 2023
    Assignees: BIONTECH SE, GENMAB A/S
    Inventors: Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
  • ANTIBODY THERAPY
    Publication number: 20230310599
    Abstract: The present invention relates to combination therapy within the field of oncology; in particular to combination therapy with vaccines and binding agents binding to CD3 and to a target antigen on tumor cells.
    Type: Application
    Filed: September 2, 2021
    Publication date: October 5, 2023
    Inventors: Hreinn BENONISSON, Jim MIDDELBURG, Thorbald VAN HALL, Isil ALTINTAS, Kristel KEMPER, Janine SCHUURMAN, Katy Ann LLOYD, Vitalijs OVCINNIKOVS, Gijsbertus ZOM
  • ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF
    Publication number: 20230212301
    Abstract: The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: November 14, 2022
    Publication date: July 6, 2023
    Inventors: Andreea Ioan, Frank Beurskens, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Isil Altintas, Pauline L. de Goeje, David Satijn, Peter Boross, Ugur Sahin, Friederike Gieseke, Alexander Muik, Kristina Schödel
  • ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF
    Publication number: 20230109496
    Abstract: The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: September 6, 2022
    Publication date: April 6, 2023
    Inventors: Andreea Ioan, Frank Beurskens, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Isil Altintas, Pauline L. de Goeje, David Satijn, Peter Boross, Ugur Sahin, Friederike Gieseke, Alexander Muik, Kristina Schödel
  • Humanized or chimeric CD3 antibodies
    Patent number: 11613575
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: March 28, 2023
    Assignee: GENMAB A/S
    Inventors: Edward Norbert Van Den Brink, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Isil Altintas, Paul Parren, Rik Rademaker
  • MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137
    Publication number: 20230089969
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Application
    Filed: August 3, 2022
    Publication date: March 23, 2023
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Friederike GIESEKE, Ugur SAHIN
  • ANTIBODIES FOR USE IN THERAPY
    Publication number: 20230087164
    Abstract: The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer. The method comprises administering to a subject, a binding agent comprising a first binding region binding to human CD137 and a second binding region binding to human PD-L1. The amount of binding agent administered in each treatment cycle is preferably about 0.3-5 mg/kg body weight or about 25-400 mg in total.
    Type: Application
    Filed: February 4, 2021
    Publication date: March 23, 2023
    Inventors: Ugur SAHIN, Alexander MUIK, Isil ALTINTAS, Ulf FORSSMANN, Kate SASSER, Maria JURE-KUNKEL, Manish GUPTA
  • BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF
    Publication number: 20230087745
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Application
    Filed: August 24, 2022
    Publication date: March 23, 2023
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Ugur SAHIN, Friederike GIESEKE, Alexander MUIK, Christian GRUNWITZ, Edward VAN DEN BRINK, Dennis VERZIJL
  • HUMANIZED OR CHIMERIC CD3 ANTIBODIES
    Publication number: 20230027394
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: May 9, 2022
    Publication date: January 26, 2023
    Inventors: Rik RADEMAKER, Isil Altintas, Patrick Engelberts, Janine Schuurman, Paul Parren
  • HUMANIZED OR CHIMERIC CD3 ANTIBODIES
    Publication number: 20220389101
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: May 9, 2022
    Publication date: December 8, 2022
    Inventors: Rik RADEMAKER, Isil ALTINTAS, Patrick ENGELBERTS, Janine SCHUURMAN, Paul PARREN
  • HUMANIZED OR CHIMERIC CD3 ANTIBODIES
    Publication number: 20220380464
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: May 9, 2022
    Publication date: December 1, 2022
    Inventors: Rik RADEMAKER, Isil ALTINTAS, Patrick ENGELBERTS, Janine SCHUURMAN, Paul PARREN
  • Binding agents binding to PD-L1 and CD137 and use thereof
    Patent number: 11459395
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: October 4, 2022
    Assignees: GENMAB A/S, BIONTECH SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Ugur Sahin, Friederike Gieseke, Alexander Muik, Christian Grunwitz, Edward Van den Brink, Dennis Verzijl
  • Multispecific antibodies against CD40 and CD137
    Patent number: 11440966
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: September 13, 2022
    Assignees: GENMAB A/S, BIONTECH SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
  • Humanized or chimeric CD3 antibodies
    Patent number: 11359015
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: June 14, 2022
    Assignee: GENMAB A/S
    Inventors: Rik Rademaker, Isil Altintas, Patrick Engelberts, Janine Schuurman, Paul Parren
  • MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137
    Publication number: 20220064317
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Application
    Filed: June 28, 2021
    Publication date: March 3, 2022
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Friederike GIESEKE, Ugur SAHIN
  • MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137
    Publication number: 20220033510
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Application
    Filed: June 28, 2021
    Publication date: February 3, 2022
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Friederike GIESEKE, Ugur SAHIN
  • ANTIBODY FORMULATION
    Publication number: 20210369842
    Abstract: The present invention relates to pharmaceutical formulations of binding agents and their use in medicine. In particular, the invention relates to pharmaceutical formulations of binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the pharmaceutical formulations of the invention and to methods for producing pharmaceutical formulations.
    Type: Application
    Filed: November 6, 2019
    Publication date: December 2, 2021
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Ugur SAHIN, Friederike GIESEKE, Alexander MUIK
  • MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137
    Publication number: 20210317225
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Application
    Filed: June 11, 2021
    Publication date: October 14, 2021
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Friederike GIESEKE, Ugur SAHIN